Drug to slow Alzheimer’s well tolerated outside of clinical trial setting

The Food and Drug Administration’s approval in 2023 of lecanemab — a novel Alzheimer’s therapy shown in clinical trials to modestly slow disease progression — was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease. But side effects — brain swelling and bleeding — emerged during clinical trials that have left some patients and physicians hesitant about the treatment.

Continue Reading

News Source: www.sciencedaily.com